CV Sciences, Inc. (CVSI): Results of Operations and Financial Condition
CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer
How this was made
The 30-second read
Why it matters
Q2 2026 results show revenue pressure and continued losses, while management attributes the decline to restrictive federal and state regulations. The company also emphasizes expense reductions and product/e-commerce expansion, but the cash balance is low.
Market read
Traders can update CVSI’s near-term fundamentals using the newly disclosed quarterly revenue, margin, operating expense reductions, adjusted EBITDA loss, and cash balance, plus the regulatory delay narrative.
What to watch
The excerpt notes 44% of net revenue came from new products launched since 2023 and that a new e-commerce platform (PlusHLTH.com) launched, which could support future conversion even if Q2 was weak.
Background
CV Sciences is an OTC-listed consumer wellness company focused on hemp extracts and related wellness products, with recent results framed around regulatory constraints.
Ticker impact
CV Sciences reported Q2 2026 revenue of $3.0M, down from $3.6M a year ago, citing restrictive hemp regulations impacting sales volume.
Likely bearish bias for the next session as traders weigh declining revenue, negative adjusted EBITDA, and low cash ($0.3M).
This is a primary 8-K earnings-style disclosure with multiple concrete negatives (revenue decline, operating loss, adjusted EBITDA loss, cash balance) and a clear driver (regulatory restrictions). However, no guidance or balance-sheet financing details are included in the excerpt, limiting conviction on magnitude of repricing.
Market effects
Highlights ongoing regulatory overhang for hemp-derived cannabinoid products, which can pressure demand and unit sales for similarly positioned nutraceutical firms.
No clear regional transmission beyond US regulatory impact mentioned.
Limited, as the cited regulatory driver is US federal and certain state restrictions.
Counterpoint
Gross margin stayed relatively stable (48.6% vs 48.9% sequentially) and operating expenses fell, suggesting cost discipline could offset some revenue pressure if regulations ease.
Key entities
- companyCV Sciences, Inc.
Subject of the 8-K, reporting Q2 2026 financial results and operational/regulatory highlights.
- governmentU.S. Senate
Voted to approve a continuing resolution delaying restrictive provisions for hemp-derived cannabinoid products, per the filing.